focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re: Partner Company

7 Nov 2006 10:24

Amphion Innovations PLC07 November 2006 Amphion Innovations Partner Company Durham Scientific Crystals Closes £875,000 Financing London, UK - 7 November 2006 - Amphion Innovations plc today announces that itsPartner Company, Durham Scientific Crystals Ltd. (DSC), a Durham Universityspin-out developing state-of-the-art semiconductor materials for the medicalimaging and security imaging markets, has raised an initial £875,000 at £2 pershare for the first close of a larger Series F financing. Amphion now owns 26.3%of Durham Scientific Crystals which is now valued at £8.3m post money. DSC has developed a breakthrough technology that is significant in thetransition from analogue to digital x-ray imaging. The Company hascommercialised the use of materials based on cadmium telluride, the premierchoice for use as digital detectors of x-rays and gamma rays, and will allow forsignificantly improved imaging in markets such as airport security and medicalimaging. Cadmium telluride materials are currently too expensive and too difficult toproduce to be used in large scale commercial applications. DSC, however, hasdeveloped a breakthrough production method to produce these crystals from avapour phase, rather than the conventional liquid based techniques, enabling thecrystals to be produced at an attractive cost and quality enabling their largescale commercial use in the future. The transformation to digital x-ray scanners in security imaging will be asignificant improvement as the technology will allow much faster screening anddirect 'fingerprinting' of dangerous materials such as liquid bombs and plasticexplosive, which are currently hard to distinguish from other plastics. In medical imaging, cadmium telluride will offer significant advantages over thecurrent materials including greater sensitivity to x-rays to enable fasterimaging and lower dosing, and will increase the ability to understand diseases,such as Alzheimer's and Cancer, and detect them in their early stages, The capital raised in this latest round of financing will support continuedresearch and development, staffing and overhead expenses. DSC is also workingwith non-commercial partners to optimise its crystals with electrode technologythat makes it easier to integrate them into the electronic infrastructure ofscanners. Richard C.E. Morgan, Chief Executive Officer of Amphion, said: "Due to the recent security issues in our airports, and the continued desire todiagnose and treat diseases earlier, there is a large growing need for faster,more effective and clearer digital imaging. We believe that DSC has thetechnology to meet these needs and this financing signifies that our investorsand partners see DSC as a company poised for tremendous growth and value thetechnology and recognise its prospects." Dr Arnab Basu, Chief Executive Officer of Durham Scientific Crystals, said: "We are excited by the response of the investment community and these funds willallow us to accelerate our R&D as we further continue to commercialise ourproducts to significantly improve imaging in the security and medical markets." For further information please contact: Amphion Innovations plcJosh Berkman, Media Relations +1 (646) 747-7158 Financial Dynamics +44 207 269 7169Ben AtwellJohn Gilbert About Amphion Innovations plc Amphion Innovations plc is listed on the AIM Exchange in London under the symbolAMP. Amphion's business is the formation, financing, management and developmentof life sciences and technology companies, working in partnership withcorporations, governments, universities and entrepreneurs seeking tocommercialize their intellectual property. Durham Scientific Crystals, Ltd. Durham Scientific Crystals, Ltd. is a research and development company, whichwas spun-out from the Physics Department of the University of Durham. Thecompany was formed in April 2003 and has been actively involved in the researchand development of semiconductor materials, in conjunction with the Universityresearch labs. DSC's technological expertise is a result of over three decadesof semiconductor research at the University of Durham. DSC is located in Sedgefield, County Durham, England and is developingnext-generation proprietary products and processes based around keysemiconductor optoelectronic materials used in medical and securityapplications. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jul 20155:07 pmRNSHolding(s) in Company
23rd Jun 20158:47 amRNSPartner Company raises £22 million
23rd Jun 20157:00 amRNSPreliminary Results
5th Jun 20157:00 amRNSPlacing to raise £1.54 million
19th May 20152:35 pmRNSAppointment of broker
15th Apr 20157:01 amRNSFDA Results
7th Apr 20157:00 amRNSShares Issued for Exercised Warrants
2nd Apr 20157:01 amRNSFirst Day of Dealings of Amphion Partner Company
24th Mar 20153:28 pmRNSIssue of Shares
20th Mar 20157:01 amRNSMotif Bio Ltd Update Re Intention to Float
26th Feb 20157:00 amRNSIssue of Equity
9th Feb 20157:00 amRNSDirector/PDMR Shareholding
2nd Feb 20154:18 pmRNSReissue: Partner Company's Intention to Float
2nd Feb 20158:00 amRNSPartner Company's Intention to Float on AIM
22nd Jan 20151:15 pmRNSDirector/PDMR Shareholding
19th Jan 20157:00 amRNSLandmark Acquisition & Update by Partner Company
6th Jan 20157:00 amRNSDataTern Receives Favourable Appeal Ruling
24th Sep 20147:00 amRNSDirectors' Dealings
19th Sep 20147:00 amRNSHalf Yearly Report
9th Sep 20147:00 amRNSAdditional Draws on Loan Facility
28th Aug 20147:00 amRNSDirectorate Change
7th Aug 20144:51 pmRNSResult of AGM and EGM
10th Jul 20149:10 amRNSDirectors' Dealings
8th Jul 20147:00 amRNSAmphion Partner Motif Can Help Solve Health Crisis
20th Jun 20147:00 amRNSNotice of EGM
18th Jun 20147:00 amRNSFinal Results
5th Jun 20147:00 amRNSNew Loan Facility
14th Apr 20147:00 amRNSAppeal Ruling
7th Apr 20145:03 pmRNSDirector/PDMR Shareholding
28th Jan 20147:00 amRNSConvertible Promissory Note Extension
12th Dec 20137:00 amRNSUpdate on Covertible Promissory Note
13th Nov 20134:33 pmRNSDirector/PDMR Shareholding
13th Nov 20137:00 amRNSPartner Company Update
16th Oct 20137:02 amRNSPartner Company IPO
24th Sep 20137:00 amRNSHalf Yearly Report
12th Sep 20137:02 amRNSPartner company Kromek seeks IPO on AIM
13th Aug 20135:16 pmRNSResult of AGM
1st Jul 201312:02 pmRNSDirector/PDMR Shareholding
28th Jun 20137:00 amRNSFinal Results
18th Apr 20137:00 amRNSDirector/PDMR Shareholding
17th Apr 20137:00 amRNSTrading Statement
28th Mar 20137:02 amRNSChange of Adviser
19th Dec 20127:00 amRNSHolding(s) in Company
13th Dec 20127:00 amRNSFundraising
5th Dec 20127:00 amRNSAmphion announces new partnership with Motif
3rd Oct 20127:00 amRNSDirector/PDMR Shareholding
28th Sep 20124:24 pmRNSDirector/PDMR Shareholding
19th Sep 20127:00 amRNSHalf Yearly Report
29th Aug 20127:00 amRNSUpdate - patent litigation
27th Jul 20127:00 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.